ClinicalTrials.gg
CompletedNCT01181115Avonex ChinaUpdated Sep 16, 2013

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)

A Phase 3 interventional study of Avonex in Multiple Sclerosis, sponsored by Biogen. Completed at 10 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-09-16.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
20th of 34
60 · median 85
Started
2010
with 1 other
Phase 3
7 of 34
none open now
Registered
25th of 34
by date
Lead sponsor
15 of 34
Biogen

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 20th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 25th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).

Read the detailed description

This is a multicenter, open-label, safety study to support registration of Avonex in China by providing data on the effect of weekly IM administration of 30mcg Avonex on safety parameters in Chinese patients with clinically diagnosed relapsing MS. This study will also include an intra-subject exploratory comparison of pre-treatment MRI (at -3 months and at month 0) and post -treatment MRI (at month 3 and month 6). Up to 60 subjects with relapsing forms of MS will be recruited to approximately 6 sites in China.

The study period will consist of screening, a 6 month open-label treatment period, and follow up at 30 days post-dosing. There will be a total of 8 clinic visits and 1 telephone contact.

Screening: will be determined 3 months +/- 7 days prior to subjects' first dose of Avonex on Day 1, at which time a screening MRI with and without Gd-enhancement will be performed.

Treatment Period: consists of eligible patients undergoing pre-dosing assessments and receiving the first dose of Avonex on day 1. Subjects will have a brain MRI within 48 hours prior to the first injection of Avonex.

Weekly doses of open-label Avonex 30mcg IM will be administered for 24 consecutive weeks for a total of 25 injections per subject. Subjects or their caregivers will be allowed to self-inject after successful completion of appropriate IM injection training.

Subjects will return to the clinic at weeks 6, 12, 18 and 24 for safety and laboratory assessments (including blood sample collection for pharmacodynamic (neopterin) and immunogenicity testing), and clinician injection site assessments. Subjects will undergo brain MRI with and without Gd enhancement at week 12 and week 24. Subjects will perform injection site pain assessments on day 1 and at weeks 6, 12, 18, and 24 recording results on a visual analog scale. Subjects who prematurely discontinue Avonex may remain in the study and continue protocol-scheduled visits/evaluations (with the exception of subject and clinician injection site assessments and neopterin sample collection.

Subjects who experience new or worsening symptoms suggestive of an MS relapse will have a neurological worsening visit within 5 days following onset of symptoms. Treatment of confirmed MS relapses will follow a protocol-specified regimen.

Post treatment period: subjects will undergo follow-up assessment at week 24 (at 24+/- 8 hours following their last Avonex injection, if applicable). Subjects will have a telephone follow up contact conducted 30 (+/- 7 days) after their last study visit to assess AEs and use of concomitant medications.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Chinese Patients
  • Relapsing MS
  • Safety
  • Avonex
  • Tolerability
  • Gadolinium
  • Interferon Beta 1a
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand risks of study and provide .
  • Must be Chinese, aged 18 to 55 years inclusive at time of consent.
  • Must have diagnosis of relapsing MS of 3 months duration at time of screening visit.
  • Must have at least 1 documented MS attack within 3 years of Day 1.
  • Must have EDSS score of 0 to 5 inclusive at screening visit.
  • All male subjects \& female subjects of must practice effective during the study.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS.
  • Have had a clinical MS attack within the 50 days prior to Day 1, and or the subject has not stabilized from a previous attack in the opinion of the Investigator.
  • The subject is unable to undergo a brain MRI scan for any reason.
  • The subject's screening and Day 1 MRIs are both normal (negative) for lesions consistent with MS (Gd-enhancing lesions are not required, but one of the 2 MRIs should be consistent with MS).
  • History of severe allergic or anaphylactic reactions.
  • Known allergy to any component of the Avonex Formulation.
  • History of any cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal or other major disease.
  • Subjects with a history of malignant disease, including solid tumors, and hematologic (except basal cell and squamous cell carcinomas of the skin that have been completely excised and considered cured).
  • History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Day 1.
  • History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 6 months prior to Day 1. Note: subjects receiving ongoing antidepressant therapy will not be excluded from the study unless the medication has been increased within the 6 months prior to Day 1.
  • Clinically significant abnormal values as determined by the Investigator.
  • Known history of (HIV).
  • Known history of, or positive test result for virus (test for hepatitis C virus antibody HCV Ab) or virus (test for Hepatitis B surface Antigen HBsAg) and/or Hepatitis B Core Antibody (HBcAb).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Active treatment

    Interferon treatment for MS

    Drug: Avonex

Interventions

  • DrugAvonex

    Interferon treatment for MS

06

What researchers measure

Primary outcomes

  1. The number and proportion of subjects with adverse events (AEs)

    Time frame: 24 weeks

  2. Assessment of clinical laboratory parameters

    Time frame: 24 weeks

  3. Assessment of vital signs and physical examinations

    Time frame: 24 weeks

  4. Assessment of electrocardiogram (ECG)

    Time frame: 24 weeks

  5. Assessment of immunogenicity

    Time frame: 24 weeks

  6. Incidence of depression

    Time frame: 24 weeks

  7. Incidence of flu-like symptoms

    Time frame: 24 weeks

  8. Subject assessment of injection site pain

    Time frame: 24 weeks

  9. Clinical assessment of the injection site

    Time frame: 24 weeks

Secondary outcomes

  1. Assess safety of Avonex by evaluating changes in the Expanded Disability Status Scale (EDSS) score over time

    Time frame: 24 weeks

  2. Number of Gd-enhancing lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment

    Time frame: at month 3 and month 6

  3. Number of new or newly enlarging T2-weighted lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment

    Time frame: at month 3 and month 6

  4. Volume of T2-weighted lesions on brain MRI scans taken after 6 months following initiation of Avonex treatment

    Time frame: month 6

  5. Assess pharmacodynamic response to Avonex by evaluating the change from baseline in serum levels of neopterin

    Time frame: 24 weeks

07

Study locations

10 sites
  • Research Site
    Baotou, China
  • Research Site
    Beijing, China
  • Research Site
    Changchun, China
  • Research Site
    Chengdu, China
  • Research Site
    Guangzhou, China
  • Research Site
    Hangzhou, China
  • Research Site
    Nanchang, China
  • Research Site
    Shanghai, China
  • Research Site
    Taiyuan, China
  • Research Site
    Xi'an, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2010
First posted
Aug 13, 2010
Start
Apr 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Sep 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01181115
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Aug 13, 2010
Start date
Apr 2010
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Sep 16, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion